Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by   Joan Lo   and   Romain Neugebauer.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            1.422
         
        
        
     
 
    
        
        - 
            Racial/ethnic differences in hip and diaphyseal femur fractures. Osteoporos Int. 2014 Sep; 25(9):2313-8.
            
            
                Score: 0.461
            
         
        
        - 
            Applying ethnic-specific bone mineral density T-scores to Chinese women in the USA. Osteoporos Int. 2016 12; 27(12):3477-3484.
            
            
                Score: 0.267
            
         
        
        - 
            Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskelet Disord. 2020 Dec 03; 21(1):801.
            
            
                Score: 0.180
            
         
        
        - 
            Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women. JAMA Netw Open. 2020 12 01; 3(12):e2025190.
            
            
                Score: 0.180
            
         
        
        - 
            Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. J Manag Care Spec Pharm. 2019 Jun; 25(6):719-723.
            
            
                Score: 0.162
            
         
        
        - 
            The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 2016 Apr; 85:142-7.
            
            
                Score: 0.128
            
         
        
        - 
            Determinants of Oral Bisphosphonate Use Beyond 5 Years. J Manag Care Spec Pharm. 2020 Feb; 26(2):197-202.
            
            
                Score: 0.043